pp-097 Gel

Indication: Prevention of new basal cell carcinoma (BCC) lesions in adults with Gorlin syndrome, a rare genetic condition with high propensity for BCC formation Clinical stage: Late clinical development — Phase 3 global clinical trial underway with top‑line results anticipated in late 2026 Modality: Small molecule, topical gel formulation Mechanism / Target: Hedgehog signaling pathway blocker targeting the SMO receptor to reduce aberrant pathway activity driving BCC lesion formation Route / form: Topical administration; 2% gel formulation intended for chronic use on the skin Differentiation: First‑in‑class topical hedgehog pathway inhibitor designed specifically for BCC prevention with minimal systemic adverse effects compared with oral hedgehog inhibitors